Patents by Inventor Priscilla S. Redd

Priscilla S. Redd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OSTEOPONTIN MONOCLONAL ANTIBODIES FOR CANCER AND OSTEOPOROSIS IMMUNOTHERAPY
    Publication number: 20240101658
    Abstract: Antibodies and antigen binding fragments thereof that immunospecifically bind OPN (OPN) and inhibit OPN activity are provided herein. The disclosed antibodies and antigen binding fragments are useful for modulating signal transduction through OPN proteins. The antibodies and antigen-binding fragments are useful for the treatment or prevention of cancer, osteoporosis, or other immune diseases.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 28, 2024
    Applicants: Augusta University Research Institute, Inc., The US Government as represented by the Department of Veterans Affairs
    Inventors: Kebin Liu, John Klement, Priscilla S. Redd
  • Osteopontin monoclonal antibodies
    Patent number: 11897950
    Abstract: Antibodies and antigen binding fragments thereof that immunospecifically bind OPN (OPN) and inhibit OPN activity are provided herein. The disclosed antibodies and antigen binding fragments are useful for modulating signal transduction through OPN proteins. The antibodies and antigen-binding fragments are useful for the treatment or prevention of cancer, osteoporosis, or other immune diseases.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: February 13, 2024
    Assignees: Augusta University Research Institute, Inc., Department of Veterans Affairs
    Inventors: Kebin Liu, John Klement, Priscilla S. Redd
  • Osteopontin Monoclonal Antibodies for Cancer and Osteoporosis Immunotherapy
    Publication number: 20210188959
    Abstract: Antibodies and antigen binding fragments thereof that immunospecifically bind OPN (OPN) and inhibit OPN activity are provided herein. The disclosed antibodies and antigen binding fragments are useful for modulating signal transduction through OPN proteins. The antibodies and antigen-binding fragments are useful for the treatment or prevention of cancer, osteoporosis, or other immune diseases.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Inventors: Kebin Liu, John Klement, Priscilla S. Redd